Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Cash from Investing Activities (2020 - 2024)

Historic Cash from Investing Activities for Gain Therapeutics (GANX) over the last 5 years, with Q4 2024 value amounting to -$43447.0.

  • Gain Therapeutics' Cash from Investing Activities fell 10138.28% to -$43447.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $5.0 million, marking a year-over-year decrease of 5130.91%. This contributed to the annual value of $5.0 million for FY2024, which is 5130.91% down from last year.
  • According to the latest figures from Q4 2024, Gain Therapeutics' Cash from Investing Activities is -$43447.0, which was down 10138.28% from -$1.0 recorded in Q3 2024.
  • Gain Therapeutics' Cash from Investing Activities' 5-year high stood at $3.1 million during Q4 2023, with a 5-year trough of -$14.9 million in Q2 2022.
  • For the 5-year period, Gain Therapeutics' Cash from Investing Activities averaged around $15516.2, with its median value being -$3156.5 (2020).
  • In the last 5 years, Gain Therapeutics' Cash from Investing Activities plummeted by 6606632.0% in 2022 and then soared by 2702626.2% in 2023.
  • Over the past 5 years, Gain Therapeutics' Cash from Investing Activities (Quarter) stood at -$14551.0 in 2020, then grew by 23.73% to -$11098.0 in 2021, then soared by 1305.89% to $133830.0 in 2022, then surged by 2247.65% to $3.1 million in 2023, then plummeted by 101.38% to -$43447.0 in 2024.
  • Its Cash from Investing Activities stands at -$43447.0 for Q4 2024, versus -$1.0 for Q3 2024 and $2.0 million for Q2 2024.